New vaccine aims to train immune system against lung cancer
NCT ID NCT01720836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1/2 trial is testing a vaccine made from a piece of the MUC1 protein, which is found on many lung cancer cells. The vaccine is mixed with an adjuvant called Poly-ICLC to boost the immune response. Thirty patients with early or locally advanced non-small cell lung cancer will receive the vaccine every three weeks for three doses, with optional yearly boosters. The goal is to see if the vaccine triggers the body to produce antibodies against MUC1, potentially helping the immune system fight the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MUC1 peptide vaccine with Poly-ICLC (Hiltonol) adjuvant
- What this could lead to
- If successful, this vaccine could train the immune system to recognize and attack lung cancer cells, potentially preventing recurrence in early-stage patients.
- What could go wrong
- This is an early phase 1/2 trial with only 30 participants, so it is too small to prove effectiveness. The vaccine may not produce a strong enough immune response or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
- New study aims to tame cholesterol side effect of lung cancer drug